In this article, we will discuss the 11 Best Cancer Stocks to Invest In Now.
Pharmaceutical companies are a blend of defensive income plays and growth opportunities. They deliver stable earnings and returns as demand for medicines, vaccines, and treatments for chronic diseases remains steady regardless of the prevailing economic cycle. That’s evident in the S&P 500 Pharmaceutical index, which is already up by more than 6%, outpacing the broader S&P 500 index, which is up by a little over 1%.
The oncology segment of the pharmaceutical sector is one of the fastest-growing, driven by the rising prevalence of cancer and advancements in targeted therapies and immunotherapies. According to Allied Market Research, the cancer drugs market is growing at a 7.2% compound annual growth rate and is projected to reach $335.2 billion by 2032.
The oncology market is poised for accelerated growth, driven by the rising incidence of cancer in ageing societies, against a backdrop of changing lifestyles and environmental factors. For starters, demand for breast cancer drugs in the US is projected to reach $6.6 billion by 2036, reflecting 5.6% growth. The robust growth comes amid high treatment penetration, established screening programs, and long-term maintenance therapy use.
Therefore, the long-term outlook for cancer drug stocks remains positive, driven by structural market growth and innovation. With that in mind, let’s take a look at some of the best cancer stocks to invest in now.
Our Methodology
To compile a list of the Best Cancer Stocks to invest in now, we scanned Cancer research ETFs, such as the Range Cancer Therapeutics ETF (CNCR) and Tema Oncology ETF (CANC). We settled on stocks with strong analyst conviction and upside potential of more than 10%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Best Cancer Stocks to Invest In Now
11. AbbVie Inc. (NYSE:ABBV)
AbbVie (NYSE:ABBV) is one of the best cancer stocks to invest in now. On February 23, AbbVie (NYSE: ABBV) announced plans to invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities. The new state-of-the-art facilities at the Illinois campus are to integrate advanced manufacturing technologies with artificial intelligence.
Artificial intelligence integration is part of AbbVie’s push to support and accelerate the development of next-generation neurosciences and obesity medications. Construction of the facilities is scheduled to begin in spring 2026 and come online in 2029. The construction of the state-of-the-art facility is part of the company’s $100 billion commitment towards research and development in the US.
“By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients,” said Robert A. Michael, chairman and chief executive officer, AbbVie.
AbbVie has already reiterated its plans to expand its manufacturing capabilities and capacity in the US. It has already broken ground on the first phase of the investment, with plans for a new chemical synthesis facility that will enable the return of API production for select neuroscience, immunology, and oncology products from Europe and Asia to the U.S.
AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on discovering and developing targeted therapies for blood cancers and solid tumors. Its oncology portfolio and research pipeline heavily feature antibody-drug conjugates (ADCs), targeted protein degradation, CAR-T cell therapies, and bispecific antibodies.
10. Revolution Medicines, Inc. (NASDAQ:RVMD)
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company has made significant progress in developing a broad portfolio of RAS(ON) inhibitors across multiple disease settings.
Daraxonrasib, a pioneering RAS(ON) multi-selective inhibitor, has already shown an unprecedented clinical profile in various combinations. Consequently, the company is enrolling patients in the US for a Phase 3 trial of RASolve 301 in Non-Small Cell Lung Cancer (NSCLC).
On the other hand, Zoldonrasib, an innovative RAS(ON) G12D-selective covalent inhibitor, has shown a highly differentiated safety and tolerability profile.
“We expect a pivotal readout from RASolute 302 in the first half of 2026, which represents an important milestone for daraxonrasib, for patients with pancreatic cancer, and for our RAS(ON)-targeting strategy overall,” Goldsmith said.
Revolution Medicines exited 2025 in a strong financial position with $2 billion in cash, cash equivalents, and marketable securities. Research and development expenses surged to $294.9 million in the fourth quarter of 2025 from $188.1 million in the fourth quarter of 2024. The increase was driven by higher clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib, and elironrasib. Full-year R&D expense totaled $987.3 million compared to $592.2 million in 2024
Net loss in the fourth quarter nearly doubled to $364.9 million, compared with $194.6 million in the same quarter of the prior year. The full-year 2025 net loss came in at $1.1 billion, compared to $600.1 million in 2024.
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage oncology company focused on discovering and developing targeted therapies for RAS-addicted cancers, which represent roughly 30% of new cancer diagnoses.
